OncoMatch/Clinical Trials/NCT05765084
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Is NCT05765084 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Dendritic cell vaccination and Atezolizumab for malignant pleural mesothelioma.
Treatment: Dendritic cell vaccination · Atezolizumab · Platinum/pemetrexed based chemotherapy — In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Disease stage
Required: Stage I, II, III, IV
Performance status
WHO 0–1
Prior therapy
Cannot have received: any treatment for MPM
Prior treatment for MPM
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: immune checkpoint blockade therapy
Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/μL) without G-CSF; lymphocyte count ≥ 0.5 x 10^9/L (500/μL); platelet count ≥ 100 x 10^9/L (100,000/μL) without transfusion; hemoglobin ≥ 90 g/L (9 g/dL), may be transfused
Kidney function
creatinine ≤ 1.5 x ULN
Liver function
AST, ALT, ALP ≤ 2.5 x ULN (≤ 5 x ULN with liver/bone metastases); total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN with Gilbert disease); albumin ≥ 25 g/L (2.5 g/dL)
Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening: ... (see full criteria above)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify